

ATC codes: J01DD04

Indication	Gonococcal infection <span style="border: 1px solid #0070C0; border-radius: 10px; padding: 2px 10px;">ICD11 code: 1B0Z</span>
INN	Ceftriaxone
Medicine type	Chemical agent
Antibiotic groups	 WATCH
List type	Core
Additional notes	Do not administer with calcium and avoid in infants with hyperbilirubinaemia.
Formulations	Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML) ; 500 mg in vial powder for injection (as sodium salt)
EML status history	First added in 2017 (TRS 1006) Changed in 2023 (TRS 1049)
Sex	All
Age	Adolescents and adults
Age restriction	> 41 weeks corrected gestational age
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">Ceftriaxone</a>
DrugBank	<a href="#">Ceftriaxone</a>

### Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - replacing the oral liquid formulation of azithromycin (200 mg/5 mL) with powder for oral liquid 200 mg/5 mL on the EML and EMLc.

### EML recommendations: Gonococcal infection

#### First choice

ceftriaxone

co-prescribed with [azithromycin](#)

#### Second choice

cefixime

co-prescribed with [azithromycin](#)

spectinomycin

gentamicin

